29 May 2020

We are delighted to share PHARMAC’s decision to fund Creon Micro from Monday, 1 June 2020, through an agreement with Mylan New Zealand Limited.

Creon Micro is a modified-release granule formulation of pancreatic enzymes. This formulation allows for smaller doses of the medicine to be administered.

Until now many parents and caregivers were portioning out the amount needed from the funded capsules into a child’s food. This led to wastage of the left over medicine and possible risk of giving the child the wrong amount. 

The dose can be measured with the special scoop prior to mixing with food or fluids, for use in infants and children who are unable to swallow capsules.

Cystic Fibrosis NZ submitted a letter of support earlier in the year, outlining the benefits that access to Creon Micro would have on our young Kiwis with CF and their family.

“CFNZ is delighted to support the funding of Mylan’s Creon Micro. The first years following diagnosis of CF are a stressful time for new parents and anything that can ease the load on families and whānau is most welcome,” says Jane Bollard.

“Creon Micro will greatly improve dosage accuracy and ease of use of the medication meaning a happier baby and family” Jane continues.

Read PHARMAC’s full notification here >